Bristol-Myers Squibb에 대한 매도 수량은 투자자에게 Bristol-Myers Squibb의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Bristol-Myers Squibb (NYSE:BMY) 주식, 공매도 수량 보고

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Government

Health Care

Retail Sales

Global

Startups

Small Business

AVGO

DKNG

HOOK

QCOM

SBGI

블록에 신규 등장 베라 브래들리(NASDAQ:VRA)의 매출이 감소했다. 이 핸드백 브랜드의 최대 주주인 Fund 1 Investments LLC는 이에 불만을 나타냈다. 12월 30일 이사회에 보낸 서한에서 공동 창립자인 바바라 브래들리 바엑가르드(Barbara Bradley Baekgaard)의 디자인을 &#34;상징적&#34;이고 &#34;수십 년간 혁신과 파괴의 대명사&#34;라고 언급했다.

딜 디스패치: 베라 브래들리는 명암이 혼재된 핸드백, 모델스의 전 CEO가 파티 시티를 탐색

Biotech

Specialty ETFs

Politics

ETFs

General

AMGN

SCHD

슈왑 미국 배당주 ETF(NYSE:SCHD)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. SCHD 펀드가 하락한 이유를 살펴보자.

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Ratings for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $61.44, along with a high estimate of $73.00 and a low estimate of $39.00. This upward trend is evident, with the current average reflecting a 11.47% increase from the previous average price target of $55.12.
<img src="https://www.benzinga.com/files/images/story/2025/1738069278_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Bristol-Myers Squibb by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$63.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$61.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$57.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Bristol-Myers Squibb's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bristol-Myers Squibb's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bristol-Myers Squibb analyst ratings.</a>
<h2>Delving into Bristol-Myers Squibb's Background</h2>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Financial Milestones: Bristol-Myers Squibb's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Bristol-Myers Squibb's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 8.44%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Bristol-Myers Squibb's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 10.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.29%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bristol-Myers Squibb's debt-to-equity ratio surpasses industry norms, standing at 3.0. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings)

Citigroup analyst Andrew Baum maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and raises the price target from $60 to $65.

Price Target

Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $65

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$35.5K</td>
<td>6.0K</td>
<td>2.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$150.00</td>
<td>$66.4K</td>
<td>7.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$42.0K</td>
<td>3.0K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.50</td>
<td>$109.6K</td>
<td>31.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>INMB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$25.5K</td>
<td>2.1K</td>
<td>486</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$590.00</td>
<td>$45.0K</td>
<td>291</td>
<td>275</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>567</td>
<td>261</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$25.4K</td>
<td>511</td>
<td>220</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$62.50</td>
<td>$44.9K</td>
<td>137</td>
<td>189</td>
</tr>
<tr>
<td>BAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.00</td>
<td>$36.8K</td>
<td>68</td>
<td>160</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bearish sentiment. It expires in 354 day(s) on January 16, 2026. Parties traded 163 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $35.5K, with a price of $218.0 per contract. There were 6058 open contracts at this strike prior to today, and today 2167 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $150.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.4K, with a price of $336.0 per contract. There were 7225 open contracts at this strike prior to today, and today 1758 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option trade with bearish sentiment. It expires in 25 day(s) on February 21, 2025. Parties traded 200 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $42.0K, with a price of $210.0 per contract. There were 3069 open contracts at this strike prior to today, and today 1262 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bearish, expiring in 354 day(s) on January 16, 2026. This event was a transfer of 522 contract(s) at a $27.50 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $109.6K, with a price of $210.0 per contract. There were 31825 open contracts at this strike prior to today, and today 1191 contract(s) were bought and sold. 
• For INMB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>), we notice a call option sweep that happens to be bullish, expiring in 235 day(s) on September 19, 2025. This event was a transfer of 75 contract(s) at a $10.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $25.5K, with a price of $340.0 per contract. There were 2116 open contracts at this strike prior to today, and today 486 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on January 31, 2025. Parties traded 200 contract(s) at a $590.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $225.0 per contract. There were 291 open contracts at this strike prior to today, and today 275 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option sweep that happens to be bullish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 252 contract(s) at a $30.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $135.0 per contract. There were 567 open contracts at this strike prior to today, and today 261 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $510.0 per contract. There were 511 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 53 day(s) on March 21, 2025. This event was a transfer of 156 contract(s) at a $62.50 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.9K, with a price of $288.0 per contract. There were 137 open contracts at this strike prior to today, and today 189 contract(s) were bought and sold. 
• For BAX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), we notice a call option trade that happens to be bullish, expiring in 718 day(s) on January 15, 2027. This event was a transfer of 80 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $36.8K, with a price of $460.0 per contract. There were 68 open contracts at this strike prior to today, and today 160 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

INMB

ISRG

SWTX

TEVA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

<ul>
<li>Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up</li>
<li>Late-breaking data presented in oral session at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium with same-day Publication in The Lancet</li>
<li>CheckMate -8HW previously demonstrated that Opdivo plus Yervoy reduced the risk of disease progression or death by 79% compared to investigator's choice of chemotherapy</li>
<li>Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer</li>
</ul>

Reported Saturday, Bristol Myers Squibb Shares New Data Showing Opdivo Plus Yervoy Improves Outcomes Compared To Opdivo Alone in Colorectal Cancer

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Initiation

Movers

Trading Ideas

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 34% of the investors opened trades with bullish expectations and 61% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $407,249 and 17, calls, for a total amount of $1,998,519.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $65.0 for Bristol-Myers Squibb during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $50.0 to $65.0, over the past month.
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737487832_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.95</td>
<td>$6.75</td>
<td>$6.85</td>
<td>$55.00</td>
<td>$510.3K</td>
<td>8.7K</td>
<td>801</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$55.00</td>
<td>$360.1K</td>
<td>12.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$263.2K</td>
<td>12.3K</td>
<td>1.6K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.55</td>
<td>$6.4</td>
<td>$6.55</td>
<td>$52.50</td>
<td>$149.3K</td>
<td>1.9K</td>
<td>229</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$136.8K</td>
<td>12.3K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Bristol-Myers Squibb Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,648,166, with BMY's price up by 1.13%, positioned at $56.92.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 16 days.</li>
</ul>
<h3>Professional Analyst Ratings for Bristol-Myers Squibb</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Bristol-Myers Squibb, maintaining a target price of $65. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Markets

Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Large Cap

Regulations

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

On Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) agreed to acquire Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940221/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-i" rel="noreferrer noopener">approximately $14.6 billion</a>.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41752158/intra-cellular-therapies-treatment-reduces-schizophrenia-relapse-risk-63" rel="noreferrer noopener">Intra-Cellular Therapies&#8217; Treatment Reduces Schizophrenia Relapse Risk 63%</a>
With this agreement, Johnson &amp; Johnson adds Intra-Cellular Therapies&#8217; Caplyta&nbsp;(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer&#8217;s disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements and strengthens Johnson &amp; Johnson&#8217;s current areas of focus.
In December 2024, Intra-Cellular Therapies submitted a marketing application to the FDA for Caplyta&nbsp;as an adjunctive treatment for adults with major depressive disorder (MDD).
In two global Phase 3 studies, Caplyta, as an adjunctive treatment to antidepressants, demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms, as measured by both clinician-rated and patient-reported outcomes.
If approved, Caplyta&nbsp;has the potential to be the first treatment approved for MDD and depressive symptoms associated with bipolar I and II in more than 15 years.
Additional Phase 3 trials are underway with Caplyta in bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania).
Johnson &amp; Johnson expects to fund the transaction through cash on hand and debt.
In 204, Bristol-Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) added an oral medication for&nbsp;schizophrenia via Karuna Therapeutics deal for $330 per share in cash for a total equity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">value of $14 billion</a>.
In November, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released data from its two Phase 2 EMPOWER trials of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" rel="noreferrer noopener">emraclidine for schizophrenia</a>.
The patients experienced an acute exacerbation of psychotic symptoms and did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics.
Price Action: JNJ stock is up 0.86% at $143.28, and ITCI stock is up 34.5% at $127.62 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42945266/why-department-store-chain-macys-stocks-are-sliding-on-monday-premarket" target="_blank" rel="noreferrer noopener">Why Is Department Store Chain Macy&#8217;s Stock Sliding Today?</a></li>
</ul>
Photo by Tada Images via Shutterstock

ITCI

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

This milestone further strengthens the collaboration to advance next-generation T cell therapies for the treatment of solid tumors.
ArsenalBio remains eligible for additional milestone payments as the programs and collaboration advance, as well as royalties on potential commercial sales.
 &nbsp;

ArsenalBio Says Bristol Myers Squibb Exercised Its Exclusive License Option For AB-4000 Series

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BMY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Bristol-Myers Squibb. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 70% bearish. Among these notable options, 2 are puts, totaling $167,800, and 8 are calls, amounting to $640,598.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $43.0 to $60.0 for Bristol-Myers Squibb over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Bristol-Myers Squibb options trades today is 3581.67 with a total volume of 2,064.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Bristol-Myers Squibb's big money trades within a strike price range of $43.0 to $60.0 over the last 30 days.
<h3>Bristol-Myers Squibb Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736539218_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$55.00</td>
<td>$268.8K</td>
<td>10.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$6.0</td>
<td>$60.00</td>
<td>$106.8K</td>
<td>1.5K</td>
<td>183</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.6</td>
<td>$13.65</td>
<td>$14.32</td>
<td>$43.00</td>
<td>$71.6K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$55.00</td>
<td>$70.7K</td>
<td>10.9K</td>
<td>247</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$7.45</td>
<td>$7.45</td>
<td>$52.50</td>
<td>$65.5K</td>
<td>1.5K</td>
<td>89</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Bristol-Myers Squibb's Current Market Status</h3>
<ul>
<li>Trading volume stands at 5,399,329, with BMY's price down by -1.0%, positioned at $56.24.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>What Analysts Are Saying About Bristol-Myers Squibb</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $67.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $70. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Bristol-Myers Squibb, which currently sits at a price target of $65. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

On Tuesday, Alger launched the Alger Russell Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVN#NYSE">INVN</a>), another addition to its lineup of funds aiming to cash in on <a href="https://www.benzinga.com/topic/etf">transformative market opportunities. </a>
The <a href="https://www.prnewswire.com/news-releases/alger-and-ftse-russell-launch-the-alger-russell-innovation-etf-ticker-invn-to-capture-the-next-wave-of-market-disruptors-302342157.html">ETF </a>comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative underdogs with high potential. At least 80% of the fund&#8217;s total assets are invested in securities of the Alger Russell Innovation Index, according to the fund&#8217;s prospectus.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878368/xrp-etf-very-soon-likely-next-after-bitcoin-and-ethereum-ripple-president-says">XRP ETF &#8216;Very Soon,&#8217; Likely Next After Bitcoin And Ethereum, Ripple President Says</a>
BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) are among the top holdings, accounting for 2.11%, 2.01%, and 2.03% as of Jan. 7. The fund&#8217;s portfolio consists of about 50 holdings.
The index uses a quantitative methodology to identify innovation-driven equities, shortlists them based on lower cash flow margins and then ranks them based on research and development expenditures. The top 50 companies on this ranking are then selected, with each stock constituting around 2% of the portfolio.
Brad Neuman, CFA, Alger's Director of Market Strategy, thinks that this approach could bring innovation &#8220;out of the shadow of financial statements&#8221; and into accessible investment instruments.
The launch of INVN makes it the sixth Alger ETF available on U.S. markets. Among its other offerings, the Alger Mid Cap 40 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRTY#NYSE">FRTY</a>) stands out with over $70 million in assets under management.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a></li>
</ul>
Photo: Shutterstock

New ETFs

BMRN

FRTY

INVN

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised the price target for Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from $375 to $400. Needham analyst Scott Berg maintained a Buy rating. Salesforce shares closed at $324.93 on Tuesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities slashed Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) price target from $130 to $110. Truist Securities analyst Robyn Karnauskas downgraded the stock from Buy to Hold. Wendy&#8217;s shares closed at $101.02 on Tuesday. <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) from $17.5 to $26. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Intuitive Machines shares closed at $19.87 on Tuesday. <a href="https://www.benzinga.com/quote/LUNR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $311 to $357. Piper Sandler analyst Clarke Jeffries upgraded the stock from Neutral to Overweight. Autodesk shares closed at $290.82 on Tuesday. See how other analysts view this stock.</li>
<li>B of A Securities boosted Ferguson Enterprises Inc. (NYSE FERG) price target from $185 to $225. B of A Securities analyst Arnaud Lehmann upgraded the stock from Underperform to Buy. Ferguson shares settled at $172.21 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) price target from $95 to $103. Jefferies analyst Matthew Taylor upgraded the stock from Hold to Buy. GE HealthCare shares closed at $83.37 on Tuesday. <a href="https://www.benzinga.com/quote/GEHC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $265 to $300. Deutsche Bank analyst Brad Zelnick upgraded the stock from Hold to Buy. Workday shares closed at $249.68 on Tuesday.  <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted the price target for NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) from $90 to $108. Morgan Stanley analyst Alex Poon upgraded the stock from Equal-Weight to Overweight. NetEase shares settled at $89.72 on Tuesday. <a href="https://www.benzinga.com/quote/NTES/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities raised Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) price target from $62 to $65. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. Bristol-Myers Squibb shares closed at $57.14 on Tuesday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) price target from $2,150 to $1,950. JP Morgan analyst Marcelo Santos maintained a Neutral rating. MercadoLibre shares closed at $1,771.22 on Tuesday. <a href="https://www.benzinga.com/quote/MELI/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

ADSK

GEHC

LUNR

MELI

NTES

WDAY

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Truist Securities analyst Robyn Karnauskas maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Buy and raises the price target from $62 to $65.

Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65

<h1 class="wp-block-heading">New On The Block</h1>
Vera Bradley Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) <a href="https://www.benzinga.com/24/12/42439021/vera-bradley-reports-30-sales-drop-in-q3-amid-business-model-transition-stock-slips">sales are down</a>. 
The handbag brand&#8217;s largest shareholder, Fund 1 Investments LLC, isn&#8217;t happy about it. A Dec. 30 <a href="https://www.businesswire.com/news/home/20241230656224/en/Fund-1-Sends-Letter-to-Vera-Bradley%E2%80%99s-Board-of-Directors-Highlighting-the-Opportunity-for-Value-Enhancing-Strategic-Alternatives">letter</a> to the board referred to co-founder Barbara Bradley Baekgaard&#8216;s designs as &#8220;iconic&#8221; and &#8220;synonymous with innovation and disruption for decades." 
But after the compliments came the critique: Fund 1 takes issue with Vera Bradley&#8217;s questionable capital allocation, poor operational performance and a failed brand turnaround, all compounded by tough macroeconomic conditions for fashion brands. What's the solution, according to Fund 1? A "strategic alternatives process" to explore selling the company to a larger organization or taking it private.
Also for sale, as of this week:
<ul>
<li>Imagination Technologies Group Limited, a British semiconductor and software design company owned by private equity firm Canyon Bridge Capital Partners, is up for sale. Lazard is shopping it around, according to <a href="https://www.bloomberg.com/news/articles/2025-01-03/chipmaker-imagination-s-owners-tap-lazard-to-search-for-buyer?srnd=phx-deals">Bloomberg</a>. </li>
<li>Skin care startup Minimalist is considering a $350 million deal, TechCrunch <a href="https://techcrunch.com/2025/01/03/hindustan-unilever-minimalist-acquisition/?guccounter=1">reported</a>. On the buy side is Hindustan Unilever Ltd., which recently purchased Oziva and Wellbeing Nutrition. Hindustan Unilever's skincare offerings include Dove and Pond's. Jaipur-based Minimalist reported an 89% revenue growth to $40.8 million in fiscal year 2024.</li>
</ul>
<h1 class="wp-block-heading">Off The Block</h1>
SouthState Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) has finalized its $2 billion stock acquisition of Texas-based Independent Bank Group, potentially signaling a wave of regional bank mergers. Key drivers include regional bank stock price growth, lower interest rates improving deposit profitability, and anticipated deregulation under Trump&#8217;s administration.
Hookipa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) is acquiring Poolbeg Pharma in an all-stock deal. Hookipa shareholders retain rights to milestone payments from Gilead&#8217;s hepatitis B partnership and proceeds from the HB-200 program. 
See Also: <a href="https://www.benzinga.com/24/12/42726550/stanley-druckenmiller-loaded-up-on-regional-banks-ahead-of-trumps-election-win">Stanley Druckenmiller Loaded Up On Regional Banks Ahead Of Trump&#8217;s Win</a>
<h1 class="wp-block-heading">Bankruptcy Block</h1>
Mitch Modell, the ex-CEO of the Modell's sporting goods chain, wants to revive bankrupt retailers Party City and Big Lots. He plans to raise $1 billion and keep 33,000 jobs afloat. He also wishes to name his 20-something sons, Matthew and Maxwell, as co-presidents, according to the <a href="https://nypost.com/2024/12/30/business/former-modells-owner-wants-to-save-bankrupt-retailers-party-city-big-lots-our-goal-is-to-save-33k-jobs/">New York Post</a>.
Modell, known for the catchy "Gotta go to Mo's" jingle, had his eureka moment at none other than Mar-a-Lago, where he decided the struggling chains needed a sporting goods flair. His vision includes ditching Big Lots' bulky furniture and sprucing up Party City with sportswear and footwear — because nothing says "Happy Birthday" like a new pair of sneakers.
To keep prices low, Modell plans to tap factories in China, Mexico and India, courtesy of Source One Global. He's also enlisted other former CEOs, such as Larry Meyer (Forever 21) and Demos Parneros (Barnes &amp; Noble) to help evaluate the deal.
<h1 class="wp-block-heading">Notes From The Block</h1>
In 2025, the incoming Trump administration is expected to be friendlier to media conglomerates looking to conduct mergers, compared to the Biden administration. "The overwhelming mood is positive from an M&amp;A perspective," Christopher Vollmer, managing director at MediaLink, told <a href="https://variety.com/2025/biz/news/media-mergers-acquisitions-2025-deals-1236263982/">Variety</a>. "People are looking to kick off M&amp;A activity in the first quarter of 2025."
But people forget that Trump wasn&#8217;t exactly cordial to dealmakers the last time he was in office. The previous&nbsp;Trump&nbsp;administration, from 2016 to 2020, blocked and sued or threatened to block a lot of big deals. 
If you recall:
<ul>
<li>AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) and Time Warner <a href="https://www.benzinga.com/news/17/11/10748659/at-t-resists-doj-order-to-divest-time-warners-cnn-for-merger-approval">failed to ink a deal</a>. Regulators argued that it could increase prices for consumers and disadvantage rival distributors.</li>
<li>Sinclair Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) and Tribune Media faced resistance due to concerns about consolidation in the broadcast industry. Sinclair <a href="https://www.benzinga.com/m-a/24/11/41805370/jim-cramer-hopes-m-a-to-come-back-bigly-under-trump-administration">paid a hefty fee</a> for whiffing.</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), had they merged, could have affected U.S. national security, a federal <a href="https://www.investors.com/news/technology/broadcom-buyout-of-qualcomm-looking-doubtful-after-federal-probe/">probe</a> showed.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) and FanDuel: A merger of the two largest daily fantasy sports platforms was blocked to preserve competition in the industry.</li>
</ul>
The Department of Justice also mandated divestitures in major transactions. For example:
<ul>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) had to divest Celgene&#8217;s Otezla treatment to resolve concerns about reduced competition in the market for psoriasis drugs.</li>
<li>Harris Corp. was required to sell parts of its military communications business to proceed with its merger with L3 Technologies, creating the company L3Harris Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>)</li>
</ul>
These interventions reflected the DOJ's focus on preventing market dominance. Should M&amp;A volume under Trump be comparable to the last four years, deal pros can&#8217;t blame anyone but themselves. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42746253/bring-it-on-angry-birds-producer-namit-malhotra-ready-for-cinema-ai-era">&#8216;Bring It On&#8217;: Angry Birds Producer Namit Malhotra Is Ready For The AI Era Of Cinema</a></li>
</ul>

Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City

Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) revealed 10 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $239,888, and 6 were calls, valued at $312,412.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $43.0 to $75.0 for Bristol-Myers Squibb during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Bristol-Myers Squibb's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $43.0 to $75.0 in the last 30 days. 
<h3>Bristol-Myers Squibb Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735674325_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.7</td>
<td>$19.3</td>
<td>$19.3</td>
<td>$75.00</td>
<td>$119.6K</td>
<td>15</td>
<td>62</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.8</td>
<td>$0.79</td>
<td>$0.8</td>
<td>$60.00</td>
<td>$71.8K</td>
<td>1.0K</td>
<td>2.1K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.05</td>
<td>$13.4</td>
<td>$13.47</td>
<td>$43.00</td>
<td>$67.3K</td>
<td>2.9K</td>
<td>50</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.57</td>
<td>$1.78</td>
<td>$1.94</td>
<td>$55.00</td>
<td>$58.2K</td>
<td>16.9K</td>
<td>334</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.8</td>
<td>$0.79</td>
<td>$0.8</td>
<td>$60.00</td>
<td>$47.5K</td>
<td>1.0K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Bristol-Myers Squibb</h3>
<ul>
<li>With a trading volume of 3,126,940, the price of BMY is up by 0.74%, reaching $56.48.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Bristol-Myers Squibb</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $66.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Jefferies upgrades its rating to Buy with a revised price target of $70. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Neutral with a new price target of $63.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Bristol-Myers Squibb's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) short percent of float has risen 7.94% since its last report. The company recently reported that it has 27.66 million shares sold short, which is 1.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Bristol-Myers Squibb Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735659015_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bristol-Myers Squibb has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bristol-Myers Squibb's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Bristol-Myers Squibb's Recent Short Interest

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig&#x2122; (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE&#xAE; drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo&#xAE; indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy&#xAE; (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor.&nbsp;
The subcutaneous administration of Opdivo Qvantig is faster, with a three- to five-minute administration time compared to 30 minutes for IV Opdivo.&#x2A;&nbsp; Subcutaneous administration may offer flexibility to receive treatment where it is best for patients and their providers, may reduce steps required for preparation and time needed for administration.

HALO

Halozyme and Bristol Myers Squibb Secure FDA Nod for Opdivo Qvantig

Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company's growth and success. So, let's analyze whether AUPH is a buy today. Read more to find out... Canadian company, Aurinia Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/AUPH/">AUPH</a>) operates as a leading commercial-stage biopharmaceutical company. The company reported impressive financial results for the third quarter of fiscal 2024. Its revenue of $67.77 million surpassed the analysts' expectations of $57.69 million. Also, AUPH's EPS of $0.10 was above the estimate of $0.01.
Aurinia emphasizes the development and commercialization of therapies that target various diseases with insufficient medical reach. The company's LUPKYNIS is used to treat adult patients with active lupus nephritis.
During the third quarter, the company announced that the first participant received a dose in a Phase 1 study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF and APRIL. Also, in September, the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS, triggering an additional $10 million payment from Otsuka Pharmaceutical Co., Ltd.
Moreover, the biotech segment itself is continuously widening its scope beyond labs and industries. The segment's advancements and innovative solutions are transforming operations and processes across sectors like farming, food, healthcare, and so on. The global biotechnology industry market is projected to grow from $483 billion in 2024 to $546 billion in 2025, reflecting a <a href="https://www.prnewswire.com/news-releases/global-biotechnology-market-outlook-2025-driving-growth-at-13-0-cagr--marketsandmarkets-302346776.html#:~:text=DELRAY%20BEACH%2C%20Fla.%2C%20Jan,CAGR)%20of%20approximately%2013.0%25.">CAGR of 13%</a>.
Amid this robust background, AUPH's operations will flourish due to its strong financial standing and continued innovations. The company recently implemented a strategic restructuring to sharpen its focus on continued LUPKYNIS&#xAE; growth and the rapid development of AUR200. The restructuring will also enhance its operational efficiency and lower operating expense.
President and Chief Executive Officer of Aurinia, Peter Greenleaf, commented, "We are pleased to report continued strong momentum through the first nine months of the year. Going forward, our streamlined organization will enable us to lean further into key areas of the commercial LUPKYNIS business that have historically delivered optimal returns while at the same time accelerating the development of our important pipeline product, AUR200."
Shares of AUPH have surged 37% over the past six months and 52.4% over the past nine months to close its last trading session at $7.77.
Let's look at factors that could influence AUPH's performance in the upcoming months.
Robust Financials
AUPH's total net revenues increased 24.3% year-over-year to $67.77 million during the third quarter that ended September 30, 2024. Its income from operations stood at $11.75 million for the quarter.
In addition, the company's <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $14.35 million and $0.10 per share, compared to a net loss of $13.45 million and $0.09 per share during the prior year's quarter.
Also, as of September 30, 2024, the company's cash, cash equivalents, and restricted cash and total assets stood at $37.14 million and $549.36 million.
Solid Historical Growth
AUPH's revenue has grown at a CAGR of 45% over the past three years. The company's tangible book value and total assets have increased 9.9% and 15.1% over the same timeframe.
Further, over the past five years, the company's revenue and total assets have improved at CAGRs of 270% and 29.5%, respectively.
Favorable Analyst Estimates
Analysts expect AUPH's revenue for the second quarter (ending June 2025) to increase 20.6% year-over-year to $68.99 million. The consensus EPS estimate of $0.13 for the same quarter reflects an 1166.7% year-over-year improvement. Also, the company has maintained an impressive consensus history, having topped the consensus revenue and EPS estimates in three of the trailing quarters.
Additionally, Street expects the company's revenue and EPS for the fiscal year 2025 to increase 18.5% and 1715.6% year-over-year to $279 million and $0.58, respectively.
POWR Ratings Reflect Promise
AUPH's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. AUPH has an A grade for Growth, which is in sync with its impressive historical growth and solid financial performance in the last reported quarter.
In addition, the stock has a B grade for Sentiment, consistent with its favorable analysts' expectations.
AUPH is ranked #12 in the 150-stock <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry.
Beyond what I have stated above, we have also given AUPH grades for Value, Quality, Momentum, and Stability. Get access to all the AUPH Ratings <a href="https://stocknews.com/stock/AUPH/">here</a>.
Bottom Line
AUPH reported solid financial results for the third quarter of fiscal 2024. Analysts appear bullish about the company's growth prospects, driven by robust demand for its innovative product offerings, evolving consumer demands, and advanced developments in the biotech space.
Given AUPH's solid financials, optimistic analysts' estimates, and promising growth outlook, this software stock could be an ideal buy now.
How Does Aurinia Pharmaceuticals Inc. (AUPH) Stack Up Against Its Peers?
While AUPH has an overall POWR Rating of A, investors could also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry with A (Strong Buy) or B (Buy) ratings: Supernus Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/SUPN/">SUPN</a>), Taro Pharmaceutical Industries Ltd. (<a href="https://stocknews.com/stock/TARO/">TARO</a>), and Bristol-Myers Squibb Co. (<a href="https://stocknews.com/stock/BMY/">BMY</a>).
For exploring more A and B-rated medical stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AUPH shares were trading at $7.56 per share on Tuesday afternoon, down $0.21 (-2.70%). Year-to-date, AUPH has declined -15.81%, versus a -0.79% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/auph-supn-taro-bmy-is-aurinia-pharmaceuticals-poised-for-growth-in-the-biotech-space/>Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Biotech And Healthcare Stocks Poised For Gains Ahead

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12. David Risinger's ratin...

Buy Rating for Bristol-Myers Squibb Driven by Cobenfy's Strong Sales Momentum and Growth Potential

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $39...

Cautious Outlook on Bristol-Myers Squibb: Sell Rating Maintained Amid Revenue Declines and Financial Challenges

Citi raised the firm's price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...

Bristol Myers price target raised to $65 from $60 at Citi

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: General Motors (GM) reported upbeat Q4...

GM, Boeing report quarterly results: Morning Buzz

10 Undervalued Dividend Growth Stocks: January 2025

CMS aiming for more transparency in drug pricing negotiations

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)

ALAB

ALPMF

AUPH

BCLYF

BKSY

BMYMP

BPOP

CSCO

GMAB

GNMSF

HSBC

IRWD

JBLU

LEGN

LVMUY

MSFT

OKLO

SNYNF

SOUN

SUPN

TARO

TEVJF

TKPHF

TROW

TSVT

VSCO

VTRS

VWAGY

VWAPY

WTRG

Screenshot 2024-02-29 at 7.16.11 PM

ATNM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Press Releases

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Comments

Bristol-Myers Squibb

매도 수량

Bristol-Myers Squibb (NYSE:BMY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌